13. The method of claim 1 where the magnetic, dense metal particles are nickel particles with an oxide coating obtained after heating to 250 degrees centigrade for 3 to 24 hours.
14. The method of claim 1 where the reactants are from a group consisting of monoclonal antibodies, polyclonal antibodies lectins, and streptavidin.
15. The method of claim 1 where enriching desired cells is by removing undesired cells.
16. The method of claim 15 where the reactants are anti-CD8.
17. The method of claim 1 where the reactants are anti-CD15.
18. The method of claim 1 where enriching desired cells is by selecting desired cells.
19. The method of claim 18 where the reactants are anti-CD4.
20. The method of claim 15 where the undesired cells are B-cell cancer cells.
21. The method of claim 20 where the reactants are anti-CD19 or anti-CD20.
22. The method of claim 1 where the cell-based therapy involved the preparation of CAR T cells.
23. The method of claim 22 where the CAR T cells are used in autologous or allogeneric CAR T cell therapy.
24. The method of claim 1 where the magnetic, dense nickel particles are sterilized by heating to 250 degrees centigrade for an appropriate time.
25. The method of claim 1 wherein the recovery of undesired cells for the production of CAR T cells is confirmed by Flow Cytometric Analysis.